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This	 work	 presents	 the	 design	 and	 synthesis	 of	 novel	 2-phenylquinazolin-4-amine	
derivatives	 (2-12)	 and	 evaluation	 of	 their	 NAD(P)H:quinone	 oxidoreducase	 1	 (NQO1)	
inducer	activity	in	murine	cells.	Also,	molecular	docking	of	all	the	new	compounds	was	
performed	 to	 assess	 their	 ability	 to	 inhibit	 Keap1-Nrf2	 protein-protein	 interaction	
through	 occupying	 the	 Keap1	 Nrf2-binding	 domain	 which	 biologically	 leads	 to	 a	
consequent	Nrf2	accumulation	and	enhanced	gene	expression	of	NQO1.	Docking	results	
showed	that	all	compounds	have	the	ability	to	interact	with	Keap1;	however	compound	














Excessive	unbalanced	production	of	 reactive	oxygen	species	 (ROS),	namely	 superoxide	
anion	 radical	 (O2-.),	 singlet	oxygen	 (1O2),	hydroxyl	 radical	 (.OH)	and	hydrogen	peroxide	
(H2O2),	 has	 been	well	 established	 to	 be	 associated	with	many	 pathological	 conditions	









pathway7.	 This	 pathway	 is	 associated	 with	 the	 expression	 of	 more	 than	 100	
cytoprotective	 genes	 and	 their	 respective	 enzymes,	 one	 of	which	 is	NAD(P)H:quinone	
oxidoreductase	 1	 (NQO1,	 EC	 1.6.99.2).	 Under	 homeostatic	 conditions,	 Nrf2	 is	
continuously	 targeted	 for	 ubiquitination	 and	 proteasomal	 degradation	 by	 Keap1.	
However,	upon	increased	oxidative	load,	reactive	cysteine	residues	within	Keap1	serve	
as	 sensors	 for	 oxidants,	 leading	 to	 loss	 of	 its	 ability	 to	 target	 Nrf2	 for	 degradation,	




variety	 of	 oxidative	 stress-related	 ailments	 like	 cancer,	 Parkinson’s,	 Alzheimer’s	 and	
diabetes11-14.	 Design	 of	 non-covalent	 small	 molecule	 modulators	 of	 the	 Keap-Nrf2	







In	 continuation	 of	 our	 quest	 for	 new	 cytoprotective	 agents20,21,	we	 herein	 report	 the	





Melting	 points	 (uncorrected)	 were	 determined	 in	 open	 capillary	 on	 a	 Gallen	 Kamp	
melting	point	apparatus	(Sanyo	Gallen	Kamp,	UK).	Precoated	silica	gel	plates	(Kieselgel	
0.25	 mm,	 60	 F254,	 Merck,	 Germany)	 were	 used	 for	 thin	 layer	 chromatography.	 A	
developing	solvent	system	of	chloroform/methanol	(8:2)	was	used	and	the	spots	were	
detected	 by	 ultraviolet	 light.	 IR	 spectra	 (KBr	 disc)	 were	 recorded	 using	 an	 FT-IR	
spectrophotometer	 (Perkin	 Elmer,	 USA).	 NMR	 spectra	 were	 scanned	 on	 a	 NMR	
spectrophotometer	 (Bruker	 AXS	 Inc.,	 Switzerland),	 operating	 at	 500	 MHz	 for	 1H	 and	
125.76	MHz	for	13C.	Chemical	shifts	are	expressed	in	δ-values	(ppm)	relative	to	TMS	as	
an	 internal	 standard,	using	DMSO-d6	 as	a	 solvent.	Elemental	analyses	were	done	on	a	
model	2400	CHNSO	analyzer	(Perkin	Elmer,	USA).	All	the	values	were	within	±	0.4	%	of	







(0.01	 mol)	 in	 dimethylformamide	 (10	 mL)	 containing	 a	 catalytic	 amount	 of	






















8.5	 [m,	12H,	Ar-H],	9.7	 [s,	1H,	NH,	exchangeable	with	D2O].	 13C-NMR	 (DMSO-d6):	ppm	
101.4,	104.8,	108.6,	114.4,	115.8,	123.3,	126.2	(2),	128.3,	128.5,	128.8	(2),	130.6,	133.5,	







O-CH2-O],	 6.8-8.6	 [m,	 12H,	 Ar-H],	 10.2	 [s,	 1H,	 NH,	 exchangeable	 with	 D2O].	 13C-NMR	
(DMSO-d6):	 ppm	 44.5,	 101.3,	 108.4,	 108.5,	 113.4,	 120.9,	 124.2,	 127.2	 (2),	 129.1	 (2),	
132.4	 (2),	132.9,	133.3,	134.8	 (2),	146.5,	146.7,	147.7,	158.4,	163.4.	MS	m/z	 (%):	 	355	







































(C=N).	 1H-NMR	 (DMSO-d6):	 ppm	7.4-9.3	 [m,	 15H,	Ar-H],	 10.3	 [s,	 1H,	NH	exchangeable	
with	D2O].	13C-NMR	(DMSO-d6):	ppm	114.4,	121.4,	124.8,	125.6,	126.3,	126.5,	127.0	(2),	






































2891,	 2860	 (CH	 aliph.),	 1617	 (C=N).	 1H-NMR	 (DMSO-d6):	 ppm	 2.8-3.7	 [m,	 8H,	 4CH2	
Cyclo],	7.0-8.5	[m,	13H,	Ar-H],	9.9	[s,	1H,	NH	exchangeable	with	D2O].	13C-NMR	(DMSO-
d6):	ppm	49.2	(2),	66.6	(2),	114.5	(2),	115.4,	123.4	(2),	126.1,	128.3	(2),	128.5	(2),	128.8	






oC,	5%	CO2	 in	α-MEM	supplemented	with	10%	(v/v)	 fetal	bovine	serum.	Cells	 (104	per	





1:1000	prior	 to	 screening	experiments.	The	 final	 solvent	concentration	 in	 the	medium	
was	 0.1%	 (v/v)	 in	 all	 wells.	 At	 the	 end	 of	 the	 treatment	 period,	 cell	 lysates	 were	
prepared	 in	 digitonin	 and	 the	 specific	 activity	 of	 NQO1	 was	 determined	 using	
menadione	as	a	substrate	as	previously	described22.	The	Concentration	which	Doubles	










were	 built	 according	 to	 the	 default	 parameters,	with	 the	MOE	 software	 suite	 version	
10.2009.	 Geometry	 optimization	 as	 well	 as	 a	 systematic	 conformational	 search	 was	
carried	 out	 to	 an	 RMS	 gradient	 of	 0.01	 Å	 employing	 the	 ConfSearch	 module	
implemented	 in	 MOE.	 All	 computations	 were	 performed	 with	 the	 Merck	 Force	 Field	
(MMFF94s).	 To	 evaluate	 our	 compounds’	 ability	 to	 access	 and	 block	 the	Nrf2-binding	
site	 of	 Keap1,	 a	 molecular	 docking	 study	 was	 performed	 using	 the	 crystallographic	
structure	of	the	Kelch	domain	of	Keap1	obtained	from	the	Protein	Data	Bank	(PDB	ID:	
4IQK).	The	protein	target	was	prepared	for	docking	by	addition	of	the	missing	hydrogens	
and	 calculating	 the	 partial	 charges.	 Internal	 validation	 was	 performed	 to	 the	 native	
ligand	followed	by	docking	of	the	compounds	where	the	target	protein	was	kept	rigid,	
while	 ligands	were	allowed	to	rotate	 to	accommodate	 freely	 inside	the	protein	cavity.	







biologically	 active	 heterocyclic	 moieties	 to	 evaluate	 and	 explore	 their	 NQO1	 inducer	
activity.	Therefore,	4-aminoquinazoline	derivatives	2-12	were	synthesized	starting	from	
4-chloro-2-phenylquinazoline	 (1)	 as	 depicted	 in	 Scheme	 1.	 Compounds	 2-12	 were	
obtained	 in	good	yield	via	reaction	of	1	with	different	amines,	namely	5-aminoindane,	
3,4-(methylenedioxy)aniline,	 pipronylamine,	 5,6,7,8-tetrahydro-1-naphthylamine,	 1-






dimethyl	 formamide	 (Scheme	 1).	 All	 the	 synthesized	 compounds	were	 established	 on	
basis	of	elemental	analyses,	IR,	1H-NMR,	13C-NMR	and	mass	spectral	data.	IR	spectra	of	
compounds	2-12	 revealed	 the	 presence	 of	 the	 characteristic	 bands	 for	 the	 NH	 group	
ranging	 from	3441	 to	3238	cm-1,	 the	aromatic	CH	around	3100	 to	3023	cm-1,	 the	C=N	
group	from	1635	to	1609	cm-1.	1H-NMR	spectra	of	compounds	2-12	exhibited	signals	at	
δ	12.5-9.1	ppm	attributed	to	the	NH	group.	1H-NMR	spectrum	of	compound	2	revealed	




1H-NMR	 spectrum	 of	 compound	5	 gave	 a	multiplet	 at	 δ	 1.6-2.8	 ppm	 assigned	 to	 the	
4CH2	groups.	13C-NMR	spectrum	of	compound	5	revealed	signals	at	22.6,	22.6,	25.0	and	
29.6	 ppm	 attributed	 to	 the	 aforementioned	 groups.	 On	 the	 other	 hand,	 1H-NMR	
spectrum	of	 compound	10	 revealed	 the	 presence	 of	 a	 singlet	 at	 2.4	 ppm	 for	 the	 CH3	
group	and	6.2	ppm	for	the	CH	of	chromene.	13C-NMR	spectrum	of	compound	10	showed	
a	singlet	at	18.5	ppm	attributed	to	the	CH3	group,	112.7	ppm	due	to	the	chromene	CH	
and	 159.3	 ppm	 for	 the	 C=O	 group.	 	 IR	 spectrum	 of	 11	 showed	 the	 presence	 of	 a	
characteristic	 band	 at	 1697	 cm-1	 for	 the	 C=O.	 1H-NMR	 spectrum	 of	 compound	 11	
revealed	 the	 presence	 of	 a	 singlet	 at	 6.2	 ppm	 for	 the	 chromene	 CH	 group.	 13C-NMR	
spectrum	 of	 compound	 11	 showed	 signals	 at	 112.6,	 123.5	 and	 160.7	 ppm	 for	 CH	
chromene,	 CF3	 and	 C=O	 groups,	 respectively.	 1H-NMR	 spectrum	 of	 compound	 12	





NQO1	 inducer	 activity	 assessment	 represented	 in	 Figure	 1	 and	 Table	 1	 revealed	 that	












derivative	5	 and	 the	morpholinophenyl	 compound	12,	 both	displayed	weak	activity	 (a	
CD	value	was	not	reached),	with	no	clear	dose	dependence.	In	contrast,	the	naphth-1-yl	
derivative	 6	 compound	 showed	 a	moderate	 dose-dependent	 inducer	 activity	 (CD	 =	 1	
μM).	 Furthermore,	 the	 2-methyl-quinolin-4-yl	 analog	 9	 displayed	 a	moderate	 inducer	
potency	 (CD	 =	 4	 μM)	which	was	 dose-dependent,	 indicating	 that	 these	modifications	
were	 not	 much	 in	 favor	 of	 activity	 as	 compared	 to	 the	 naphthyl	 bioisostere	 6.	 The	
bioisosteres	7	and	8	demonstrated	a	big	difference	in	activity.	Whereas,	the	quinolin-2-
yl	 derivative	 7	 had	 the	 highest	 potency	 in	 this	 study	 (CD	 =	 0.4	 μM),	 the	 3	 positional	
isomer	8	 was	mre	 than	 twice	 less	 potent	 (CD	 =	 0.9	 μM).	 Finally,	 with	 regards	 to	 the	
bioisosteric	 pair	 10	 and	 11	 (CD	 =	 3	 and	 1.6	 μM,	 respectively)	 it	 was	 evident	 that	
replacement	of	 the	methyl	 group	with	 a	 triflouromethyl	 almost	 doubled	 the	potency.	
Although	almost	similar	in	potency,	compounds	6	(CD	=	1	μM)	and	8	(CD	=	0.9	μM)	were	
very	 different	 in	 terms	 of	 dose	 responsiveness.	 Thus,	 whereas	 induction	 was	 dose-
dependent	 for	 compound	 6,	 it	 was	 not	 for	 compound	 8.	 Compound	 7	 was	 the	most	


















































2	 3	 4	 5	 6	 7	 8	 9	 10	 11	 12	
0.09765	 NR*	 NR	 NR	 NR	 NR	 1.34	 NR	 NR	 NR	 NR	 NR	
0.1953	 NR	 NR	 NR	 NR	 NR	 1.49	 NR	 NR	 NR	 NR	 NR	
0.3906	 NR	 NR	 1.27	 NR	 NR	 1.81	 NR	 NR	 NR	 NR	 NR	










1.563	 1.02	 2.42	 1.53	 1.33	 2.24	 3.33	 2.36	 1.5	 1.77	 2.03	 1.66	
3.125	 0.93	 2.44	 1.66	 1.44	 2.98	 4.3	 2.39	 1.81	 2.09	 2.08	 1.45	
6.25	 0.88	 2.41	 1.71	 1.5	 3.71	 5.14	 2.2	 2.3	 2.21	 2.04	 1.53	
12.5	 0.87	 2.2	 1.78	 1.55	 4.34	 5.5	 2.12	 2.92	 2.37	 2.02	 1.47	
25	 0.81	 1.88	 1.77	 1.71	 4.69	 NR	 1.76	 3.57	 2.36	 NR	 NR	
50	 0.83	 1.7	 1.56	 1.82	 4.69	 NR	 NR	 4.61	 NR	 NR	 NR	
100	 0.8	 1.5	 NR	 1.87	 3.65	 NR	 NR	 4.82	 NR	 NR	 NR	












Keap1	 is	 known	 to	 bind	 to	 Nrf2	 promoting	 its	 degradation,	 resulting	 in	 low	 levels	 of	
cytoprotective	 gene	 products.	 Various	 small	 molecule	 compounds	 were	 reported	 to	
bind	 to	 the	 Keap1	 Kelch	 domain	 and	 antagonize	 its	 activity23,24,25.	 For	 assessing	 	 the	
newly		synthesized	compounds’	ability	to	access	and	block	the	Kelch	domain	of	Keap1,	a	




Ser508	and	Ser555	with	 S	 =	 -13.306	Kcal/mol	 and	 rmsd	0.6635	Kcal/mol/Å	 (Figure	2).	
Upon	docking	of	the	synthesized	compounds,	they	all	showed	an	arene–cation	binding	
interaction	with	Arg415	via	their	aromatic	rings.	Compound	11	(S=	-10.913	Kcal/mol)	has	






















was	 the	 only	 compound	 that	 showed	 3	 arene-cation	 interactions	 with	 Arg415	 and	 2	















the	 ability	 of	 small	 molecules	 to	 disrupt	 the	 Keap1-Nrf2	 protein-protein	 interactions.	
Therefore,	 although	 the	molecular	 docking	 study	 suggests	 that	 these	 compounds	 can	






in	activating	Nrf2,	 the	 inducer	potency	of	 compound	7	 in	upregulating	NQO1	strongly	




In	 conclusion,	 this	 study	presents	 the	 synthesis	of	N-substituted	2-phenylquinazolin-4-
amine	 based	 derivatives	 2-12	 as	 cytoprotective	 NQO1	 inducers.	 	 The	 most	 potent	
inducer	 in	this	study	was	the	analogue	7	which	caused	a	dose-dependent	 induction	of	
NQO1	with	a	CD	value	of	0.4	μM.	In	silico	evaluation	of	these	derivatives	as	Keap1-Nrf2	
protein-protein	 interaction	 inhibitors	 was	 performed	 using	 molecular	 docking	
techniques	employing	MOE	software	version	10.2009.	Derivatives	were	found	to	bind	to	
key	amino	acids	 in	 the	binding	 site	with	a	network	or	arene-arene	and	arene-cationic	
interactions.	These	molecules	represent	promising	quinazoline	scaffold-based	leads	for	
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